Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1730430 · FYE Dec 31 · Prices AT CLOSE 2026-08-20 (USD) Last $78.47 · Day −2.88% · Mkt cap $6.4B · P/E (FY) 107.7× · 1Y +136.3% · Off 52W high −5.4% · Vol (1Y) 50.1% Price2023-08-21 → 2026-08-20 KNSA close: $17.2 on 2023-08-21 to $78.5 on 2026-08-20. Split-adj closes · 240 of 2,066 · price returnⓘ At a glance | Short interest5.5% of sh out | | Days to cover5.0d | | 13F net flow (QoQ)+4.84% | | Top-10 13F concentration50.5% | | Next report (est.)2026-10-27 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)107.7× | | Sales (TTM)$754.0M | | Earnings (TTM)$73.1M | | ROE11.7% | | Net margin8.7% | | ROIC29.4% | | EPS growth 3Y−33.9% | | Sales growth 3Y45.5% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+90.2% | | 1Y+136.3% | | 3Y+356.0% | | 5Y+543.2% | | Since incept. (ann.)+18.4% |
Total return · from 2018-05-24ⓘ Risk | Ann. volatility (1Y)50.1% | | Ann. volatility (3Y)47.8% | | Sharpe (1Y)1.99 | | Sharpe (3Y)1.30 | | Max drawdown (1Y)−21.1% | | Max drawdown (3Y)−34.1% | | Beta (3Y vs SPY)0.07 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| FMR LLC | 6.8M | $329M | 8.64% | +315.4% | | Rubric Capital Management LP | 3.8M | $181M | 4.75% | +12.7% | | BAKER BROS. ADVISORS LP | 2.8M | $136M | 3.58% | +0.0% | | TANG CAPITAL MANAGEMENT LLC | 2.3M | $109M | 2.86% | +0.0% | | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8M | $85M | 2.24% | new | | ACADIAN ASSET MANAGEMENT LLC | 1.3M | $64M | 1.69% | −22.0% | | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $64M | 1.69% | new | | MORGAN STANLEY | 997,786 | $48M | 1.26% | −26.6% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-07-28 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-03-31 | 2026-04-28 | $0.27 | +145.5% | $214.3M | +55.5% | | 2025-12-31 | 2026-02-24 | — | — | $202.1M | +65.0% | | 2025-09-30 | 2025-10-28 | $0.23 | — | $180.9M | +61.2% | | 2025-06-30 | 2025-07-29 | $0.23 | — | $156.8M | +44.3% |
As-reported XBRL · next 2026-10-27 est.ⓘ Segment mixFY2025 (ended Dec 2025) Pharmaceutical 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
